Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21

Vaccine

Volumn 19, Issue 28-29, 2001, Pages 3957-3967

  Waite, Douglas C ^a   Jacobson, Eric W ^a   Ennis, Francis A ^a   Edelman, Robert ^b   White, Bernadette ^a   Kammer, Robert ^c   Anderson, Christine ^c   Kensil, Charlotte R ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c Aquila Biopharmaceuticals Inc   (United States)

Author keywords

Excipient; Injection pain; QS 21

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ADJUVANT; ALUMINUM HYDROXIDE; BENZYL ALCOHOL; POLYSORBATE 80; QS 21;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; INJECTION; INJECTION PAIN; MALE; NORMAL HUMAN; PAIN ASSESSMENT; PH; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; BENZYL ALCOHOL; BETA-CYCLODEXTRINS; CROSS-OVER STUDIES; CYCLODEXTRINS; DOUBLE-BLIND METHOD; DRUG TOLERANCE; HUMANS; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; PAIN; POLYSORBATES; SAFETY; SAPONINS;

EID: 0035898945     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00142-6     Document Type: Article

References (32)

1. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex
2. 13C-NMR spectroscopy
3. Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines
4. Impact of the saponin adjuvant QS-21 and aluminum hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi
5. Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs
6. Comparison of the effects of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate
7. Structural and immunological characterization of the vaccine adjuvant QS-21
8. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes
9. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine
10. + cytotoxic T lymphocyte responses
11. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection
12. QS-21: A water-soluble triterpene glycoside adjuvant
13. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
14. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21
15. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside; enhanced immunogenicity when combined with adjuvant
16. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2
17. Safety profile of Phase I and II preventive HIV type 1 envelope vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group
18. A preliminary evaluation of a recombinant circumsporozoite vaccine against Plasmodium falciparum malaria
19. Current perspectives on pain upon injection of drugs
20. Adverse reactions to diptheria, tetanus, pertussis-polio vaccination at 18 months of age: Effect of injection site and needle length
21. Local tolerance of subcutaneous injections
22. Blowing away shot pain: A technique for pain management during immunization
23. Excipients and their use in injectable products
24. Determination of deltoid fat pad thickness. Implications for needle length in adult immunization
25. Local tolerance of subcutaneous injections
26. Benzyl alcohol attenuates the pain of lidocaine injections and prolongs anesthesia
27. Diluting lidocaine and mepivacaine in balanced salt solution reduces the pain of intradermal injection
28. 'Inactive' ingredients in pharmaceutical products: Update
29. Benzyl alcohol as an alternative local anesthetic